The MedChemic Synthesis Group (MCSG) is committed to advancing the fields of synthetic and medicinal chemistry through the rational design and synthesis of bioactive molecules with therapeutic potential. Our research is centered on the development of heterocyclic compounds, which remain among the most privileged scaffolds in drug discovery owing to their structural diversity and broad pharmacological relevance. To achieve this goal, we employ established synthetic methodologies, with particular emphasis on molecular hybridization and cycloaddition reactions, as powerful strategies for the construction of novel molecular architectures.

In alignment with the principles of green chemistry, we strive to minimize the environmental footprint of our synthetic protocols. To this end, we integrate eco-friendly synthetic technologies such as ultrasonication, microwave-assisted synthesis, and the use of deep eutectic solvents, thereby ensuring sustainability without compromising efficiency or yield.

The bioactivity of the synthesized compounds is systematically evaluated against a spectrum of disease targets, with a focus on antidiabetic, anticancer, and antimicrobial agents. A significant component of our research is directed toward the development of novel inhibitors of Mycobacterium tuberculosis, addressing one of the most pressing global health challenges.

Our experimental research is complemented and guided by computational chemistry tools. We employ molecular docking studies, molecular dynamics simulations, and density functional theory calculations to gain insights into molecular interactions, predict physicochemical properties, and rationalize structure-activity relationships.